Longleaf Partners Fund Sells Bio-Rad Stake After Q2 Underperformance
The fund lagged the S&P 500 and Russell 1000 Value Index in Q2 2026, returning 3.87% before exiting BIO. Longleaf Partners Fund posted a 3.87% return in Q2 2026, trailing the S&P 500’s 15.20% gain and the Russell 1000 Value Index’s 13.87% advance. The underperformance prom